Kymera Therapeutics to Present New In Vivo Data Demonstrating the Broad Anti-Inflammatory Activity of its IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual MeetingGlobeNewsWire • 05/03/21
Kymera Therapeutics Honored by Boston Business Journal as a 2021 Best Places to Work CompanyGlobeNewsWire • 04/19/21
Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021GlobeNewsWire • 04/10/21
Kymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology (SID) 2021 Annual MeetingGlobeNewsWire • 04/09/21
Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory DiseasesGlobeNewsWire • 03/02/21
Kymera Therapeutics Strengthens Leadership with Key Appointments and PromotionsGlobeNewsWire • 02/03/21
Kymera Therapeutics Is A Protein Degrading Pioneer With A Triple-Figure Share Price In WaitingSeeking Alpha • 01/14/21
Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021GlobeNewsWire • 01/05/21
Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/07/20
Kymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare ConferenceGlobeNewsWire • 11/23/20
Kymera Therapeutics to Present at the Stifel 2020 Virtual Healthcare ConferenceGlobeNewsWire • 11/11/20
Kymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 11/05/20
Kymera Therapeutics to Present Data on Novel IRAKIMiD and STAT3 Protein Degraders at Virtual 62nd American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/04/20
Kymera Reports Positive Data, And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 10/13/20
Kymera Therapeutics to Deliver Two Podium Presentations at 3rd Annual Targeted Protein Degradation SummitGlobeNewsWire • 10/12/20
Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating Proof of Mechanism of an IRAK4 Degrader in Patients with Hidradenitis SuppurativaGlobeNewsWire • 10/09/20
Kymera Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare ConferenceGlobeNewsWire • 09/14/20
Kymera Therapeutics Appoints Biopharma Veterans Pamela Esposito and Jeff Albers to its Board of DirectorsGlobeNewsWire • 09/09/20
Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific OfficerGlobeNewsWire • 08/27/20
Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and Concurrent Private PlacementGlobeNewsWire • 08/25/20